Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial

JAMA

Volumn 303, Issue 4, 2010, Pages 333-340

  Wilber, David J ^a   Pappone, Carlo ^b   Neuzil, Petr ^c   De Paola, Angelo ^d   Marchlinski, Frank ^e   Natale, Andrea ^f   Macle, Laurent ^g   Daoud, Emile G ^h   Calkins, Hugh ⁱ   Hall, Burr ^j   Reddy, Vivek ^c   Augello, Giuseppe ^b   Reynolds, Matthew R ^k   Vinekar, Chandan ^l   Liu, Christine Y ^l   Berry, Scott M ^m   Berry, Donald A ⁿ  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^l Biosense Webster   (United States)

^m Berry Consultants   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; PROPAFENONE; QUINIDINE; SOTALOL; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; ATRIOESOPHAGEAL FISTULA; BAYES THEOREM; CATHETER ABLATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHRAGM PARALYSIS; DRUG WITHDRAWAL; FEMALE; FISTULA; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HOSPITAL; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERICARDIAL EFFUSION; PERICARDITIS; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY VEIN OBSTRUCTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THERAPY EFFECT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT FAILURE; MIDDLE AGED; QUALITY OF LIFE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT FAILURE;

EID: 75749090779     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.2029     Document Type: Article

References (28)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2006;48(4):854-906.
2. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. Circulation. 2003;107(23):2920-2925.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. Circulation. 1998;98(10):946-952.
4. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba Follow-up Study. Am J Med. 1995;98(5):476-484.
5. Hamer ME, Blumenthal JA, McCarthy EA, et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal superventricular tachycardia. Am J Cardiol. 1994;74(8):826-829.
6. Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation. J Am Coll Cardiol. 2006;48(4):721-730.
7. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002;143(6): 984-990.
8. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(6):628-633.
9. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342(13):913-920.
10. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2003; 42(1):20-29.
11. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18):1861-1872.
12. Calkins H, Brugada J, Packet DL, et al. HRS/EHRA/ ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007;4(6):816-861.
13. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation. JAMA. 2005;293(21):2634-2640.
14. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug refractory atrial fibrillation. Eur Heart J. 2006;27(2):216-221.
15. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. J Am Coll Cardiol. 2006;48(11):2340-2347.
16. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation. Circulation. 2008;118(24):2498-2505.
17. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I, conceptual framework and item selection. Med Care. 1992;30(6): 473-483.
18. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on healthrelated quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996; 94(7):1585-1591.
19. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci. 2004;19:175-187.
20. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005;2(4):295-300.
21. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27-36.
22. Curtis AB, Seals AA, Safford RE, et al. Clinical factors associated with abandonment of a rate-control or rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. Am Heart J. 2005; 149(2):304-308.
23. Vasamreddy CR, Dalal D, Dong J, et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2006;17(2):134-139.
24. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111(9):1100-1105.
25. Yokoyama K, Nakagawa H, Wittkampf FH, et al. Comparison of electrode cooling between internal and open irrigation in radiofrequency ablation lesion depth and incidence of thrombus and steam pop. Circulation. 2006;113(1):11-19.
26. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. J Am Coll Cardiol. 2003;42(2):185-197.
27. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for highrisk patients with atrial fibrillation. J Am Coll Cardiol. 2008;51(8):843-849.
28. Pappone C, Radinovic A, Manguso F, et al. Atrial fibrillation progression and management: a 5-year prospective follow-up study. Heart Rhythm. 2008; 5(11):1501-1507.